Brief: Kaken Pharmaceutical says distribution agreement for Clenafin in Hong Kong and Macau
02/10/2018 03:19
Oct 2(Reuters) - Kaken Pharmaceutical Co Ltd 4521.T
* Says Kaken Pharmaceutical Co Ltd (Kaken) and Main Life
Corp.,
Ltd. (Main Life) announced today that Kaken and Main Life
concluded an exclusive distribution agreement for the topical
formulation for Onychomycosis “Clenafin/Jublia” in Hong Kong and
Macau
Source text in Japanese:https://goo.gl/8DHP9K
Further company coverage: 4521.T
(Beijing Headline News)
((Beijing.HeadlineNews@thomsonreuters.com; +86 10 62674724;
Reuters Messaging: huafang.zhang.reuters.com@reuters.net))